At Capital Signals 2026, hosted by Caidya in Boston on June 10, industry leaders from biotech operations, venture investing, and investment banking came together to discuss one of the most pressing questions facing emerging biopharma companies: how to secure capital in an increasingly selective market while continuing to advance clinical development.
The discussion featured Jonathan Kornstein, Vice President of Rare Disease and Pediatrics at Caidya; Michael Cooney, PhD, Vice President at Bain Capital Life Sciences; and Ankit Aggarwal, Executive Director of Healthcare Investment Banking at J.P. Morgan. Roger Boutin, Vice President of Marketing at Caidya, moderated the conversation.
While the panel covered a range of topics, from financing trends and therapeutic area preferences to AI and global clinical development, one message surfaced repeatedly: capital has returned to biotech, but investors are demanding greater evidence, clearer differentiation, and stronger execution than they were just a few years ago.
Biotech Funding Has Rebounded, but Investor Expectations Have Changed
Panelists noted that financing conditions improved significantly during the second half of 2025 and have remained favorable throughout 2026. Improved macroeconomic stability, encouraging clinical trial outcomes, a healthier IPO market, and continued M&A activity have all contributed to renewed investor confidence.
But unlike the pandemic-era biotech boom, investors are no longer willing to fund companies based solely on promising science or platform potential.
Aggarwal emphasized that today’s financing environment rewards companies that can clearly articulate why they deserve capital now and what meaningful milestones they will achieve with that investment. Investors are increasingly focused on clinical de-risking, disciplined capital allocation, and well-defined value inflection points.
In other words, access to capital has improved, but competition for that capital remains intense.
Where Investors Are Focusing Their Attention
When asked which therapeutic areas are attracting the greatest interest, the panel highlighted several sectors that continue to generate significant investor enthusiasm.
Oncology remains the largest area of investment, driven by ongoing innovation, substantial commercial opportunities, and continued demand from pharmaceutical acquirers. Cardio-metabolic diseases and immunology also remain highly attractive, supported by recent clinical and commercial successes that have reinforced investor confidence in both categories.
The panel also pointed to growing interest in central nervous system (CNS) programs. As scientific understanding advances and investors look beyond increasingly crowded therapeutic areas, CNS has begun to regain momentum as a source of new investment opportunities.
Several panelists noted that investor interest ultimately comes down to the strength of the science and the magnitude of the unmet need being addressed. The most compelling opportunities continue to be those built around differentiated approaches that have the potential to improve patient outcomes in meaningful ways.
What Makes an Asset Investable?
A significant portion of the discussion focused on how investors evaluate opportunities in today’s market.
Across both public and private markets, three themes consistently emerged: clinical validation, differentiation, and value creation.
Investors increasingly want evidence that a therapy works before assigning significant value. The era of premium valuations for purely preclinical stories has largely passed, particularly in a market where investors have more opportunities to choose from.
Differentiation has become equally important. With multiple companies often pursuing similar targets and mechanisms, investors want to understand what makes a program distinct and why it has the potential to outperform competing approaches.
The panel also emphasized the importance of near-term value inflection points. Programs with meaningful clinical milestones expected within the next 12 to 24 months tend to attract greater interest than those facing longer timelines and less defined development paths.
Management quality continues to play a major role as well. Teams with demonstrated experience executing development programs, raising capital, and creating shareholder value often have a meaningful advantage when engaging investors.
Clinical Development Strategy and Financing Strategy Are Increasingly Connected
From an operational perspective, Kornstein highlighted how closely clinical development decisions and financing outcomes have become linked.
For emerging biotech companies, investor discussions often come back to two questions: How much will the trial cost, and how long will it take?
The ability to generate proof-of-concept data efficiently can significantly influence a company’s fundraising prospects. Development strategies that shorten timelines, accelerate patient enrollment, and reach critical milestones sooner can improve both capital efficiency and investor confidence.
As a result, clinical execution is no longer viewed solely as an operational challenge. Increasingly, it is a financing strategy as well.
Global Clinical Development Is Becoming a Competitive Advantage
The discussion also explored China’s growing role in global clinical research and drug development.
Panelists cited several advantages that continue to attract sponsor interest, including faster study startup timelines, accelerated patient enrollment, lower development costs, and access to large patient populations. They also noted the increasing level of innovation emerging from Chinese biotechnology companies themselves.
At the same time, the speakers emphasized the importance of carefully evaluating how clinical data generated in one region will apply across broader patient populations. Regulatory expectations regarding diversity, global development strategies, and data applicability remain important considerations.
Panelists generally agreed that China is becoming an increasingly important component of global development planning, particularly for companies seeking faster and more capital-efficient paths to proof of concept.
Early-Stage Companies Continue to Face Funding Challenges
Although financing conditions have improved overall, the panel acknowledged that raising capital remains particularly challenging for preclinical and very early-stage companies.
The discussion also surfaced several practical considerations for early-stage companies seeking capital.
First, companies should ensure they are targeting investors whose mandates align with their stage of development and therapeutic focus. Not every investor participates across the entire company lifecycle, and understanding investor fit can significantly improve fundraising efficiency.
Second, early-stage companies should think carefully about building the right capital stack. Family offices, angel investors, and specialized seed-stage venture funds often play a critical role in helping companies generate the data needed to attract larger institutional investors later.
For rare disease companies, regulatory milestones such as Orphan Drug Designation can also provide meaningful external validation and strengthen the overall investment thesis.
Finally, the panel stressed the importance of relationship building. Successful fundraising efforts often begin long before capital is required, and companies that engage investors early are generally better positioned when financing opportunities arise.
AI Is Generating Interest, but Clinical Data Still Drives Value
Artificial intelligence was an unavoidable topic of discussion, reflecting the broader excitement surrounding AI-enabled drug discovery and development.
While the panel expressed optimism about AI’s potential, the discussion remained grounded in practical considerations.
Investors remain focused on outcomes rather than technology branding. Simply incorporating AI into a company narrative is unlikely to justify a premium valuation on its own.
As Cooney emphasized, the core questions investors ask have not fundamentally changed: Does the drug work? Does it address an important unmet need? And does it offer meaningful differentiation?
AI may help companies answer those questions more efficiently, but clinical evidence remains the primary determinant of value.
Key Takeaways
The biotech financing environment in 2026 is healthier than it has been in several years, but capital is being deployed selectively and with greater discipline.
For emerging biotech companies, success increasingly depends on generating meaningful proof-of-concept data, demonstrating clear differentiation, maintaining disciplined development plans, identifying near-term value inflection points, and building relationships with investors whose interests align with the company’s stage and strategy.
Perhaps the most important takeaway from the discussion is that innovation continues to attract capital, but only when it is supported by strong execution and credible evidence. Investors are demanding more evidence and greater execution discipline than in previous market cycles, but the fundamental equation remains unchanged: strong science, paired with thoughtful development and operational excellence, continues to create value.
Capital Signals 2026 was hosted by Caidya in Boston on June 10, 2026. The panel featured Jonathan Kornstein (Caidya), Michael Cooney, PhD (Bain Capital Life Sciences), and Ankit Aggarwal (J.P. Morgan), and was moderated by Roger Boutin (Caidya).